TABLE 2.

Reactivity of convalescent-phase sera from WNV encephalitis patients, one SLEV encephalitis patient, and normal controls with WNV, SLEV, and/or recombinant WNV E protein domain III antigens in indirect IgG ELISA, HI test, and PRNT₉₀ test

Serumb	Absorbance in IgG indirect ELISAa				Titer in HI		WNV PRNT90
	WNV Ag	SLEV Ag	r-EIII Ag	BSA	WNV	SLEV
026	1.772	0.301	2.486	0.034	5,120	320	≥2,560
022	1.644	0.387	0.751	0.024	1,280	20	1,280
071	1.885	0.388	1.822	0.021	640	160	640
028	0.876	0.216	0.831	0.023	640	<20	160
034	1.187	0.252	0.683	0.031	320	40	160
017	0.847	0.175	0.396	0.017	640	<20	80
008	0.685	0.235	0.328	0.030	160	<20	80
016	0.790	0.172	0.333	0.029	40	<20	80
025	1.099	0.238	0.162	0.055	40	<20	40
015	0.572	0.205	0.146	0.026	40	<20	40
031	0.545	0.231	0.084	0.022	40	<20	20
050	0.156	0.280	0.026	0.025	<20	40	<20
C1	0.117	0.140	0.020	0.022	<20	<20	<20
C2	0.093	0.121	0.020	0.020	<20	<20	<20
C3	0.086	0.130	0.054	0.056	<20	<20	<20
C4	0.125	0.153	0.046	0.033	<20	<20	<20

^aAbsorbance values given are means of triplicate wells. Sera were screened against WNV and SLEV antigens and the r-EIII protein at a 1:100 dilution. BSA-coated wells were used as a control for nonspecific binding of antibodies.

^bSamples C1 to C4 were obtained from flavivirus naive donors; sample 050 was obtained from an SLEV encephalitis patient.